{"entity":{"id":"nct04495153","kind":"trial","name":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","aka":[],"tldr":"A phase 2 trial of Aglatimagene besadenovec in non-small-cell lung cancer and small-cell lung cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.","summary":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC is a phase 2 interventional study registered as NCT04495153 by Candel Therapeutics, Inc., with 90 participants enrolled, started 2020-10-13 and due to reach its primary completion in 2024-12-31. Interventions recorded: Aglatimagene besadenovec. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04495153","url":"https://clinicaltrials.gov/study/NCT04495153"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["aglatimagene-besadenovec"],"companies":["candel-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04495153","phase":"2","setting":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients","sponsor":"Candel Therapeutics, Inc.","participation":[{"nct":"NCT04495153","source":"https://clinicaltrials.gov/study/NCT04495153","fetchedAt":"2026-10-07T16:53:21.208Z","studySha256":"c2e6a01215e49f2d021f7741ad31e464c061c5bc5c2637cea83c1652683f637f","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2025-08-22","leadSponsor":"Candel Therapeutics, Inc.","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":90,"enrolmentType":"ACTUAL","siteCount":14,"recruitingSiteCount":0,"countries":["United States"]}],"started":"2020-10-13","startedType":"actual","enrolled":90,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04495153/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"aglatimagene-besadenovec","kind":"drug","name":"Aglatimagene besadenovec","route":"/drugs/aglatimagene-besadenovec/"}],"company":[{"id":"candel-therapeutics","kind":"company","name":"Candel Therapeutics","route":"/companies/candel-therapeutics/"}]}}